March 27, 2025 01:10 PM EDT

With tariffs on the way, generic drugmaking woes could hinder Trump’s reshoring plan

Anna Brown

News Reporter

President Donald Trump’s threatened tariffs on pharmaceuticals are incentivizing drugmakers to build more manufacturing capacity in the US. But makers of generics likely won’t have …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With tariffs on the way, generic drugmaking woes could hinder Trump’s reshoring plan

Anna Brown

News Reporter

Sign up to read this article for free.

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

European regulator rejects Lilly's Alzheimer’s drug over potentially fatal side effects

With tar­iffs on the way, gener­ic drug­mak­ing woes could hin­der Trump’s reshoring plan

Anna Brown

News Reporter

Sign up to read this article for free.

more like this

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

Eu­ro­pean reg­u­la­tor re­jects Lil­ly's Alzheimer’s drug over po­ten­tial­ly fa­tal side ef­fects

With tariffs on the way, generic drugmaking woes could hinder Trump’s reshoring plan

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

European regulator rejects Lilly's Alzheimer’s drug over potentially fatal side effects